A 6-Week Time Period May not be Sufficient to Identify Potential Adverse Events Following COVID-19 Vaccination

H. Banoun, P. Provost
{"title":"A 6-Week Time Period May not be Sufficient to Identify Potential Adverse Events Following COVID-19 Vaccination","authors":"H. Banoun, P. Provost","doi":"10.21203/rs.3.rs-2327212/v1","DOIUrl":null,"url":null,"abstract":"Background. Messenger RNA (mRNA) vaccines have been widely used as the main sanitary measure destined to fight the COVID-19 pandemic. Rapidly purported as being “safe and effective”, this new generation of vaccines is radically different from those developed traditionally and for which potentially associated adverse events (AEs) are considered through a standard 6-week post-vaccination period. \nHypothesis. Here, we posit that the reporting period for AEs related to the COVID-19 vaccines may need to be longer. \nMethod. In this retrospective, observational study, we aimed to assess the chronology of new/worsening ailments occurring after the administration of COVID-19 vaccines based on the changes to the participants’ pharmacological records. Patients vaccinated against COVID-19 and experiencing health-related events during the study period (between September 30, 2021 and July 15, 2022) were included and the changes to their pharmacological records were analyzed. \nResults. One hundred and twelve (112) adult patients (63 men, 49 women; 67.54 ± 14.55 years-old; mean ± standard deviation) have reported changes to their pharmacological record following health-related events, which occurred 11.57 weeks (median; range 0.04-47.14) following their last COVID-19 injection of 3 doses (median; range 1-4). The most frequent medical ailments that appeared or worsened were cardiovascular diseases (CVD; N=61), cancer (N=31), respiratory diseases (RD; N=22) and zona (N=10), half of which occurred after the second dose. Nineteen (19) patients (10 men, 9 women; 78.2 ± 11.4 years-old) died on average 17.14 weeks (SD 13.71) after their last injection. \nConclusion. Most (76.1%) of the health-related events experienced by patients vaccinated against COVID-19 occurred beyond the 6-week period prescribed by the health authorities. Our findings call for further investigations and an extension of the post-vaccination AE reporting period.","PeriodicalId":391540,"journal":{"name":"International Journal of Vaccine Theory, Practice, and Research","volume":"14 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Vaccine Theory, Practice, and Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21203/rs.3.rs-2327212/v1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

Background. Messenger RNA (mRNA) vaccines have been widely used as the main sanitary measure destined to fight the COVID-19 pandemic. Rapidly purported as being “safe and effective”, this new generation of vaccines is radically different from those developed traditionally and for which potentially associated adverse events (AEs) are considered through a standard 6-week post-vaccination period. Hypothesis. Here, we posit that the reporting period for AEs related to the COVID-19 vaccines may need to be longer. Method. In this retrospective, observational study, we aimed to assess the chronology of new/worsening ailments occurring after the administration of COVID-19 vaccines based on the changes to the participants’ pharmacological records. Patients vaccinated against COVID-19 and experiencing health-related events during the study period (between September 30, 2021 and July 15, 2022) were included and the changes to their pharmacological records were analyzed. Results. One hundred and twelve (112) adult patients (63 men, 49 women; 67.54 ± 14.55 years-old; mean ± standard deviation) have reported changes to their pharmacological record following health-related events, which occurred 11.57 weeks (median; range 0.04-47.14) following their last COVID-19 injection of 3 doses (median; range 1-4). The most frequent medical ailments that appeared or worsened were cardiovascular diseases (CVD; N=61), cancer (N=31), respiratory diseases (RD; N=22) and zona (N=10), half of which occurred after the second dose. Nineteen (19) patients (10 men, 9 women; 78.2 ± 11.4 years-old) died on average 17.14 weeks (SD 13.71) after their last injection. Conclusion. Most (76.1%) of the health-related events experienced by patients vaccinated against COVID-19 occurred beyond the 6-week period prescribed by the health authorities. Our findings call for further investigations and an extension of the post-vaccination AE reporting period.
6周的时间可能不足以确定COVID-19疫苗接种后的潜在不良事件
背景。信使RNA (mRNA)疫苗已被广泛用作对抗COVID-19大流行的主要卫生措施。这种新一代疫苗被迅速宣称为“安全有效”,与传统疫苗截然不同,传统疫苗的潜在相关不良事件(ae)是在接种后标准的6周内考虑的。假设。在这里,我们假设与COVID-19疫苗相关的不良反应报告周期可能需要更长。方法。在这项回顾性观察性研究中,我们旨在根据参与者药理学记录的变化,评估接种COVID-19疫苗后发生的新发/恶化疾病的年表。纳入了在研究期间(2021年9月30日至2022年7月15日)接种COVID-19疫苗并经历与健康相关事件的患者,并分析了其药理学记录的变化。结果。112例成人患者(男63例,女49例);67.54±14.55岁;(平均±标准偏差)的患者报告在发生与健康相关的事件后药理学记录发生变化,发生时间为11.57周(中位数;范围0.04-47.14),最后一次注射3剂COVID-19(中位数;范围1 - 4)。出现或恶化最常见的内科疾病是心血管疾病(CVD;N=61),癌症(N=31),呼吸系统疾病(RD;N=22)和带状区(N=10),其中半数发生在第二次给药后。19例患者(男10例,女9例;(78.2±11.4岁),平均在末次注射后17.14周死亡(SD 13.71)。结论。在接种COVID-19疫苗的患者中,大多数(76.1%)与健康相关的事件发生在卫生当局规定的6周之后。我们的研究结果要求进一步调查和延长疫苗接种后AE报告期。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信